Cardiovascular (CV) events in patients with cancer can be caused by concomitant CV risk factors, cancer itself, and anticancer therapy. Since malignancy can dysregulate the hemostatic system, predisposing cancer patients to both thrombosis and hemorrhage, the administration of dual antiplatelet therapy (DAPT) to patients with cancer who suffer from acute coronary syndrome (ACS) or undergo percutaneous coronary intervention (PCI) is a clinical challenge to cardiologists. Apart from PCI and ACS, other structural interventions, such as TAVR, PFO-ASD closure, and LAA occlusion, and non-cardiac diseases, such as PAD and CVAs, may require DAPT. The aim of the present review is to review the current literature on the optimal antiplatelet therapy and duration of DAPT for oncologic patients, in order to reduce both the ischemic and bleeding risk in this high-risk population.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144375 | PMC |
http://dx.doi.org/10.3390/jcdd10040135 | DOI Listing |
Alzheimers Dement
December 2024
Central University of Punjab, Bathinda, Punjab, India.
Background: Neuroinflammation has gained substantial attention for its involvement in the progression of Alzheimer's disease (AD).
Method: Recently, it was discovered that platelets, which make up 90% of the circulatory Aβ, encourage the development of AD. Therefore, we hypothesized to use a novel coumarin derivative PS21HKR, which is believed to possess anti-platelet and anti-inflammatory properties for the treatment of AD.
J Int Med Res
January 2025
Department of Surgery, Chonnam National University Hospital, Gwangju, Republic of Korea.
The popliteal artery segment is particularly challenging for endovascular treatment. Stents used for treating popliteal artery lesions are usually associated with an increased risk of stent fracture and re-occlusion. The Supera stent is designed to withstand mechanical stress, with a low risk of fracture.
View Article and Find Full Text PDFIschemic stroke is a significant global health problem associated with mortality and disability. Intracranial atherosclerotic stenosis (ICAS) is a leading cause of stroke and contributes to recurrent stroke, especially in Asian population. Because of the different pathophysiology and mechanisms of ICAS resulting in ischemic stroke compared to extracranial atherosclerotic stenosis (ECAS), treatment strategies for secondary prevention would be different.
View Article and Find Full Text PDFTranspl Int
January 2025
Erasmus Medical Center Transplant Institute, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands.
The prevention of hepatic artery thrombosis (HAT) is pivotal for graft survival immediately after liver transplantation (LT). This study aimed to identify risk factors (RF) for early HAT (eHAT) and assess the benefit of antiplatelet prophylaxis (AP). This retrospective single-center study included 836 adult patients who underwent LT between 2007 and 2022.
View Article and Find Full Text PDFNeurol Res Pract
January 2025
Goethe University Frankfurt, University Hospital, Department of Neurology, Schleusenweg 2-16, 60528, Frankfurt am Main, Germany.
Background: Advances in secondary stroke prevention, including direct oral anticoagulants (DOACs), dual antiplatelet therapies (DAPT), and cardiovascular risk management, have changed costs over the past decade. This study aimed to evaluate annual treatment costs and trends in drug-based secondary prophylaxis after ischemic strokes.
Methods: Annual treatment costs were evaluated using the net costs per defined daily dosage (DDD) of discharge medications for ischemic stroke patients treated in 2020 at the University Hospital Frankfurt, Germany.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!